Drugs for Autosomal Dominant Polycystic Kidney Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 134)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Candesartan cilexetil |
Approved |
Phase 4 |
|
145040-37-5 |
|
Synonyms:
1-(Cyclohexylocarbonyloxy)ethyl-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-1H-benzimidazole-7-carboxylate
1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-ethoxy-1-{[2'-(2H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-1,3-benzodiazole-7-carboxylic acid
1-Cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylic acid
Amias
Atacand
Blopress
CANDESARTAN
|
Candesartan cilexetil
Kenzen
Parapres
RATACAND
TCV 116
TCV-116
|
|
2 |
|
Curcumin |
Approved, Investigational |
Phase 4 |
|
458-37-7, 84765-67-3 |
969516 |
Synonyms:
1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione
1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione
14a-Methyl-9,19-cyclo-5a,9b-cholestane-3b,6a-diol
C.I. 75300
C.I. natural yellow 3
CI natural yellow 3
CI-75300
Cucurmin
Curcuma
CURCUMIN
Curcumin I
Diferaloylmethane
Diferuloylmethane
e 100
E100
E-100
Gelbwurz
Golden seal
Haidr
Halad
Haldar
Halud
|
Hydrastis
INS NO. 100(I)
INS-100(I)
Kacha haldi
Merita earth
Natural yellow 3
NSC-32982
NSC-687842
Orange root
Safran d'inde
Souchet
Terra merita
Tumeric yellow
Turmeric
Turmeric (>98% curcurmin)
Turmeric oleoresin (79%-85% curcumin)
Turmeric yellow
Yellow ginger
Yellow puccoon
Yellow root
Yellow, turmeric
Yo-kin
|
|
3 |
|
Pravastatin |
Approved |
Phase 4 |
|
81093-37-0 |
54687 |
Synonyms:
(+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoate
(+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
(3R,5R)-7-[(1S,2S,6S,8S,8AR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
3beta-Hydroxycompactin
Apo pravastatin
Apo-pravastatin
Apotex brand OF pravastatin sodium
Aventis brand OF pravastatin sodium
Bristacol
Bristol-myers squibb brand OF pravastatin sodium
C10AA03
Compactin
Elisor
Eptastatin
Esteve brand OF pravastatin sodium
Juste brand OF pravastatin sodium
Lin pravastatin
Lin-pravastatin
Linson pharma brand OF pravastatin sodium
Lipemol
Liplat
Lipostat
Lipostat®|Pravachol®|pravastatin sodium
Mevalothin
Mevalotin
Mevastatin
Mevinolin
Nu pravastatin
Nu-pharma brand OF pravastatin sodium
Nu-pravastatin
|
Oliprevin
Prareduct
Pravachol
Pravacol
Pravaselect
Pravasin
PRAVASTATIN
Pravastatin acid
Pravastatin monosodium salt, (6 beta)-isomer
Pravastatin sodium
Pravastatin sodium salt
Pravastatin tert octylamine salt
Pravastatin tert-octylamine salt
Pravastatin, (6 beta)-isomer
Pravastatina
Pravastatina [Spanish]
Pravastatine
Pravastatine [French]
Pravastatinum
Pravastatinum [Latin]
Pravator
RMS 431
RMS-431
Sankyo brand OF pravastatin sodium
Selectin
Selektine
Selipran
Sodium salt, pravastatin
Squibb brand OF pravastatin sodium
Vasten
|
|
4 |
|
Amiloride |
Approved |
Phase 4 |
|
17440-83-4, 2016-88-8, 2609-46-3 |
16231 |
Synonyms:
3,5-Diamino-N-carbamimidoyl-6-chloropyrazine-2-carboxamide
Alphapharm brand OF amiloride hydrochloride
Amiclaran
Amidal
Amiduret trom
AMILAMONT
Amiloberag
Amilorid
Amilorida
Amilorida [INN-Spanish]
Amiloride
AMILORIDE HCL
amiloride HCl|Midamor®
Amiloride hydrochloride
AMILORIDE HYDROCHLORIDE DIHYDRATE
Amiloride hydrochloride hydrate
Amiloride hydrochloride, anhydrous
Amiloridum
Amiloridum [INN-Latin]
AMILOSPARE 5
Amipramidin
Amipramidine
Amipramizid
Amipramizide
|
Amiprazidine
AMORIDE
AMR
Amrad brand OF amiloride hydrochloride
Amyloride
Anhydrous amiloride hydrochloride
BERKAMIL
Berolina brand OF amiloride hydrochloride
Cahill may roberts brand OF amiloride hydrochloride
Douglas brand OF amiloride hydrochloride
Guanamprazin
Guanamprazine
Hydrochloride, amiloride
Hydrochloride, anhydrous amiloride
HYDRO-RIDE
Kaluril
Merck brand OF amiloride hydrochloride
Merck sharp and dohme brand OF amiloride hydrochloride
Midamor
Midoride
Modamide
N-Amidino-3,5-diamino-6-chloropyrazinecarboxamide
Trom, amiduret
Trommsdorff brand OF amiloride hydrochloride
|
|
5 |
|
Candesartan |
Experimental |
Phase 4 |
|
139481-59-7 |
2541 |
Synonyms:
2-Ethoxy-1-(p-(O-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylate
2-Ethoxy-1-(p-(O-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid
2-Ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4Ethyl]}-1H-benzimidazole-7-carboxylate
2-Ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4Ethyl]}-1H-benzimidazole-7-carboxylic acid
2-Ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate
2-Ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid
2-Ethoxy-7-carboxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methylbenzimidazole
Amias
Atacand
|
Blopress
Candesartan
Candesartan cilexetil
CANDESARTAN CILEXETIL RELATED COMPOUND G
CV-11974
CV-11974|TCV-116 (prodrug)
Ratacand
TCV-116 (PRODRUG)
|
|
6 |
|
Cilnidipine |
Investigational |
Phase 4 |
|
132203-70-4 |
2752 5282138 |
Synonyms:
(+-)-(E)-CINNAMYL 2-METHOXYETHYL 1,4-DIHYDRO-2,6-DIMETHYL-4-(M-NITROPHENYL)-3,5-PYRIDINEDICARBOXYLATE
CILNIDIPINE
|
|
|
7 |
|
Adrenergic Antagonists |
|
Phase 4 |
|
|
|
8 |
|
Adrenergic alpha-Antagonists |
|
Phase 4 |
|
|
|
9 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
10 |
|
Analgesics |
|
Phase 4 |
|
|
|
11 |
|
Antirheumatic Agents |
|
Phase 4 |
|
|
|
12 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4 |
|
|
|
13 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
14 |
|
Antimetabolites |
|
Phase 4 |
|
|
|
15 |
|
Hypolipidemic Agents |
|
Phase 4 |
|
|
|
16 |
|
Anticholesteremic Agents |
|
Phase 4 |
|
|
|
17 |
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|
Phase 4 |
|
|
|
18 |
|
Lipid Regulating Agents |
|
Phase 4 |
|
|
|
19 |
|
Sodium Channel Blockers |
|
Phase 4 |
|
|
|
20 |
|
Diuretics, Potassium Sparing |
|
Phase 4 |
|
|
|
21 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
22 |
|
Somatostatin |
Approved, Investigational |
Phase 2, Phase 3 |
|
38916-34-6, 51110-01-1 |
53481605 16129706 |
Synonyms:
(5S,8R,14R,17R,20R,23R,26R,29R,32R,35R)-38-[(2-{[(2R)-2-amino-1-hydroxypropylidene]amino}-1-hydroxyethylidene)amino]-20,35-bis(4-aminobutyl)-14,26,29-tribenzyl-7,10,13,16,19,22,25,28,31,34,37-undecahydroxy-32-[(C-hydroxycarbonimidoyl)methyl]-11-(1-hydroxyethyl)-17-[(1S)-1-hydroxyethyl]-8-(hydroxymethyl)-23-[(1H-indol-3-yl)methyl]-1,2-dithia-6,9,12,15,18,21,24,27,30,33,36-undecaazacyclononatriaconta-6,9,12,15,18,21,24,27,30,33,36-undecaene-5-carboxylate
ALA-GLY-CYCLO-[CYS-LYS-ASN-PHE-PHE-TRP-LYS-THR-PHE-THR-SER-CYS]
Growth hormone-inhibiting hormone (ghih)
L-ALANYLGLYCYL-L-CYSTEINYL-L-LYSYL-L-ASPARAGINYL-L-PHENYLALANYL-L-PHENYLALANYL-L-TRYPTOPHYL-L-LYSYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-CYSTEINE CYCLIC (3-14) DISULFIDE
SOMATOSTATIN
SOMATOSTATIN-1
SOMATOSTATIN-14
SOMATOSTATINA
|
SOMATOSTATINE
SOMATOSTATINUM
Somatotropin release-inhibiting factor (srif)
Somatotropin release-inhibiting hormone
SRIF-14
SYNTHETIC GROWTH HORMONE RELEASE-INHIBITING HORMONE
SYNTHETIC SOMATOSTATIN-14
|
|
23 |
|
Angiotensin II |
Approved, Investigational |
Phase 3 |
|
68521-88-0, 11128-99-7, 4474-91-3 |
172198 |
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
5 L Isoleucine angiotensin II
5-Isoleucine-angiotensin II
5-L-Isoleucine angiotensin II
5-L-Isoleucineangiotensin II
Ang II
ANG-(1-8)octapeptide
Angiotensin
Angiotensin 2
Angiotensin II
Angiotensin II (human)
Angiotensin II (mouse)
Angiotensin II, 5-L-isoleucine
Angiotensin-(1-8) octapeptide
Angiotonin
|
Asp-arg-val-tyr-ile-his-pro-phe
Delivert
Human angiotensin II
Hypertensin
II, 5-L-isoleucine angiotensin
Ile(5)-angiotensin II
Ile5-angiotensin II
Isoleucine(5)-angiotensin
Isoleucine(5)-angiotensin II
isoleucine5-angiotensin II
Isoleucyl(5)-angiotensin II
N-(1-(N-(N-(N-(N-(N(2)-L-a-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-alpha-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-Α-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
Valyl(5)-angiotensin II
|
|
24 |
|
Lactitol |
Approved, Investigational |
Phase 3 |
|
585-86-4 |
157355 |
Synonyms:
4-O-beta-D-Galactopyranosyl-D-glucitol
4-O-β-D-Galactopyranosyl-D-glucitol
D-Lactitol
Emportal
Importal
Lactitol
|
Lactitolum
Neda lactiv importal
Oponaf
Pizensy
WURCS=2.0/2,2,1/[H2122H][a2112h-1b_1-5]/1-2/a4-b1
|
|
25 |
|
Octreotide |
Approved, Investigational |
Phase 3 |
|
83150-76-9 |
383414 6400441 |
Synonyms:
(4R,7S,10S,13R,16S,19R)-19-{[(2R)-2-amino-1-hydroxy-3-phenylpropylidene]amino}-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
19-[(2-Amino-1-hydroxy-3-phenylpropylidene)amino]-10-(4-aminobutyl)-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-6,9,12,15,18-pentahydroxy-7-(1-hydroxyethyl)-13-[(1H-indol-3-yl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carboximidate
Compound 201 995
Compound 201995
Compound 201-995
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L- cysteinamide cyclic (2->7)-disulphide
DRG-0115|Mycapssa®|Sandostatin®|SMS 201,995
Octreotida
Octreotide
Octreotide acetate
OCTREOTIDE ACETATE (PRESERVATIVE FREE)
OCTREOTIDE ACETATE PRESERVATIVE FREE
Octreotide acetate salt
Octreotidum
|
Octrotide
Sandostatin
SANDOSTATIN LAR
Sandostatine
Sandoz 201 995
Sandoz 201995
Sandoz 201-995
SMS 201-995
SMS 201-995 AC
SMS-201-995
SMS-201-995 AC
SMS-201995-AC
SMS995
SMS-995
|
|
26 |
|
Lanreotide |
Approved |
Phase 3 |
|
108736-35-2 |
71349 6918011 |
Synonyms:
188Re-Lanreotide
2-{[(19-{[2-amino-1-hydroxy-3-(naphthalen-2-yl)propylidene]amino}-10-(4-aminobutyl)-6,9,12,15,18-pentahydroxy-16-[(4-hydroxyphenyl)methyl]-13-[(1H-indol-3-yl)methyl]-7-(propan-2-yl)-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaen-4-yl)(hydroxy)methylidene]amino}-3-hydroxybutanimidate
2-Naphthylalanyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)-threoninamide
BIM 23014
BIM 23014|DC 13-116|lanreotide acetate|Somatuline®
DC 13-116
Lanreotida
Lanreotide
Lanreotide acetate
Lanreotide acetic acid
Lanreotide-SR
|
L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide
Nal-cyclo(cys-tyr-TRP-lys-val-cys)THR-NH2
Nal-cyclo(cys-tyr-TRP-lys-val-cys)-THR-NH2
Naphthalenyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)threoninamide
Naphthyl-cyclo(cys-tyr-TRP-lys-val-cys)THR-NH2
Somatulin
Somatulina
Somatuline
SOMATULINE AUTOGEL
SOMATULINE LA
|
|
27 |
|
Carbamide peroxide |
Approved |
Phase 2, Phase 3 |
|
124-43-6 |
|
Synonyms:
Carbamide peroxide
Hydrogen peroxide carbamide
Urea dioxide
|
Urea hydrogen peroxide
Urea peroxide
|
|
28 |
|
Spironolactone |
Approved |
Phase 3 |
|
1952-01-7, 52-01-7 |
5833 |
Synonyms:
ABBOLACTONE
Acelat
Aldace
Aldactazide
Aldactide
Aldactone
Aldactone a
Aldactone®|spiractin|spirotone
Alderon
Aldopur
Almatol
Alphapharm brand OF spironolactone
Alpharma brand OF spironolactone
Alter brand OF spironolactone
Altex
Aquareduct
Ashbourne brand OF spironolactone
Azupharma brand OF spironolactone
Betapharm brand OF spironolactone
Cardel brand OF spironolactone
CAROSPIR
CT Arzneimittel brand OF spironolactone
CT, Spiro von
CT-Arzneimittel brand OF spironolactone
Deverol
Dexo brand OF spironolactone
DIATENSEC
Dira
Duraspiron
Espironolactona
Espironolactona [INN-Spanish]
Espironolactona alter
Espironolactona mundogen
Euteberol
Flumach
Frumikal
Generosan brand OF spironolactone
GX SPIRONOL
Hormosan brand OF spironolactone
Jenapharm brand OF spironolactone
Jenaspiron
Lacalmin
Lacdene
LARACTONE
Mayoly-spindler brand OF spironolactone
Melarcon
Merck dura brand OF spironolactone
Mundogen brand OF spironolactone
Nefurofan
Novo spiroton
Novopharm brand OF spironolactone
Novo-spiroton
NovoSpiroton
NSC-150399
Osyrol
Pfizer brand OF spironolactone
|
Pharmafrid brand OF spironolactone
Practon
Roche brand OF spironolactone
Sagisal
SC-9420
Searle brand OF spironolactone
Sincomen
SNL
Spiractin
Spiresis
SPIRETIC
Spiridon
SPIRNOLACTONE
Spiro l.u.t.
Spiro von CT
Spirobeta
Spiroctan
SPIROCTAN 100
SPIROCTAN 25
SPIROCTAN 50
Spiroctanie
Spiroderm
Spirogamma
Spirolactone
Spirolakton
Spirolang
Spirolone
Spirone
Spirono isis
Spironocompren
Spirono-isis
SPIRONOLACTONE
Spironolactone [BAN:INN:JAN]
Spironolactone A
Spironolactonum
Spironolactonum [INN-Latin]
Spironolattone
Spironolattone [DCIT]
Spironone
Spirospare
SPIROSPARE 100
SPIROSPARE 25
Spiro-Tablinen
SPIROTONE
Sprioderm
Supra-puren
Suracton
Uractone
Urusonin
Veroshpiron
Verospiron
Verospirone
Verospirone Opianin
Von CT, spiro
Wörwag brand OF spironolactone
Xenalon
|
|
29 |
|
Hydralazine |
Approved |
Phase 3 |
|
86-54-4 |
3637 |
Synonyms:
(1Z)-1(2H)-Phthalazinone hydrazone
(2H)-Phthalazinone hydrazone
1-Hydrazinophthalazine
1-Phthalazinylhydrazine
6-Hydralazine
APR968
Apresoline
Apressin
Apressoline
Hidral
Hidralazina
Hydralazin
HYDRALAZINE
Hydralazine hydrochloride
|
Hydralazine mono hydrochloride
Hydralazine mono-hydrochloride
Hydralazinum
Hydrallazin
Hydrallazine
Hydrazinophthalazine
Hydrazone 1(2H)-phthalazinone
Hydrochloride, hydralazine
Hypophthalin
Idralazina
mono-Hydrochloride, hydralazine
Nepresol
NSC-126699
Phthalazin-1-ylhydrazine
|
|
30 |
|
Lisinopril |
Approved, Investigational |
Phase 3 |
|
83915-83-7, 76547-98-3 |
5362119 |
Synonyms:
(S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
[N2-[(S)-1-CARBOXY-3-phenylpropyl]-L-lysyl-L-proline
Acerbon
Acercomp
Alapril
Carace
Cipral
Cipril
Coric
Inhibril
Inopril
Linopril
Linvas
Lipril
Lisinal
LISINOPRIL
Lisinopril anhydrous
LISINOPRIL DIHYDRATE
LISINOPRIL HYDRATE
Lisinopril maleate (1:1)
Lisinopril sulfate (1:2)
Lisinoprilum
Lisipril
|
Lisoril
Lispril
Loril
LPR
Lysinopril
MK-521
Noperten
Novatec
Presiten
Prinil
Prinivil
Prinivil®|Zestril®
Prinzide
Renacor
Sinopril
Sinopryl
Tensopril
Tensyn
Tersif
Vivatec
Zestoretic
Zestril
|
|
31 |
|
Telmisartan |
Approved, Investigational |
Phase 3 |
|
144701-48-4 |
65999 |
Synonyms:
4'-((1,4'-Dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylate
4'-((1,4'-Dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid
4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylate
4'-((4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid
4'-[(1,4'-Dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylate
4'-[(1,4'-Dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid
4'-[(1,7'-Dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylate
4'-[(1,7'-Dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid
BIBR 277
BIBR 277Se
BIBR-277
|
BIBR-277 SE
BIBR-277SE
BIBR-277-SE
BIBR-277SE|Kinzalmono®|Micardis®|Pritor®
C09CA07
Micardis
Micardis HCT
Pritor
TELMISARTAN
Telmisartan tablets
TOLURA
|
|
32 |
|
Diltiazem |
Approved, Investigational |
Phase 3 |
|
42399-41-7 |
39186 |
Synonyms:
(+)-cis-5-[2-(Dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester
(+)-cis-5-[2-(Dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetic acid ester
(+)-CIS-DILTIAZEM
(+)-cis-diltiazem|Cardizem®|CRD-401|D-(cis)-diltiazem|Dilacor-XR®|RG-83606
(2S,3S)-5-(2-(Dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate
(2S,3S)-5-(2-(Dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetic acid
(2S-cis)-3-(Acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one
Acalix
Acetate (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester
Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester
Adizem
Aldizem
Altiazem
Anginyl
Angizem
Anoheal
Apo-Diltiaz
Biovail brand OF diltiazem hydrochloride
Britiazim
Bruzem
Calcicard
Cardil
Cardizem
Cardizem CD
Cardizem SR
Cardizen LA
Cartia XT
Citizem
Cormax
CRD 401
CRD-401
D-(CIS)-DILTIAZEM
D-cis-Diltiazem
Deltazen
|
Dilacor
Dilacor XR
DILACOR-XR
Diladel
Dilcontin
Dilpral
Dilren
Dilrene
Dilta-Hexal
DILT-CD
Diltia
DILTIAZEM
Diltiazem hydrochloride
Diltiazem malate
Diltiazemum
Dilticard
DILTZAC
Dilzem
Dilzen
Endrydil
Herbesser
Incoril AP
Masdil
Novo-Diltazem
Nu-Diltiaz
RG-83606
Surazem
Syn-Diltiazem
TIAMATE
Tiazac
Tiazac Tildiem
Tiazac XC
Viazem
Watson pharmaceuticals brand OF diltazem
|
|
33 |
|
Metoprolol |
Approved, Investigational |
Phase 3 |
|
37350-58-6, 51384-51-1 |
4171 |
Synonyms:
(+/-)-metoprolol
(RS)-Metoprolol
1-(Isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol
Beatrolol
Beloc
Beloc duriles
Beloc-duriles
BelocDuriles
Betaloc
Betaloc astra
Betaloc-astra
BetalocAstra
Betalok
CGP-2175
CGP-2175C
CGP-2175C|GP-2175E|H-93/26|Lopressor®|Toprol®
CR-XL, Metoprolol
DL-Metoprolol
GP-2175E
H-93/26
Lopresor
Lopresoretic
LOPRESSIDONE
Lopressor
Lopressor HCT
|
Meijoprolol
Metohexal
METOPROLOL
Metoprolol CR XL
Metoprolol CR-XL
Metoprolol succinate
Metoprolol tartrate
Metoprololum
Metroprolol
Preblok
Prelis
Presolol
Seloken
Selopral
Selo-Zok
Seroken
Spesicor
Spesikor
Succinate, metoprolol
Tartrate, metoprolol
Toprol
Toprol XL
ToprolXL
Toprol-XL
|
|
34 |
|
Clonidine |
Approved |
Phase 3 |
|
4205-91-8, 4205-90-7 |
2803 20179 |
Synonyms:
2-((2,6-Dichlorophenyl)imino)imidazolidine
2,6-Dichloro-N-2-imidazolidinylidenebenzenamine
2-[(2,6-Dichlorophenyl)imino]imidazoline
Adesipress
Boehringer ingelheim brand OF clonidine hydrochloride
Catapres
CATAPRES P.L.
CATAPRES TTS 1
CATAPRES TTS 2
CATAPRES TTS 3
Catapres®|Kapvay®
Catapresan
Catapressan
Catapres-TTS
CATAPRES-TTS-1
CATAPRES-TTS-2
CATAPRES-TTS-3
Catarpres
Catarpresan
Catarpres-TTS
Chlofazoline
Chlophazolin
Chlornidinum
Clofelin
Clofenil
Clonidin
Clonidina
Clonidine
Clonidine dihydrochloride
CLONIDINE HCL
Clonidine hydrochloride
|
Clonidine monohydrobromide
Clonidine monohydrochloride
Clonidinhydrochlorid
Clonidinum
Clonidinum [INN-Latin]
Clonistada
Clopheline
CLORPRES
COMBIPRES
DICHLORANILINO IMIDAZOLIN
Dihydrochloride, clonidine
Dixarit
DURACLON
Duraclont
Gemiton
Hemiton
Hydrochloride, clonidine
Ipotensium
Isoglaucon
JENLOGA
KAPVAY
KAPVAY®
Klofelin
Klofenil
Monohydrobromide, clonidine
Monohydrochloride, clonidine
ST 155BS
ST-155
ST-155BS
ST-155-BS
Tenso-Timelets
|
|
35 |
|
Minoxidil |
Approved, Investigational |
Phase 3 |
|
38304-91-5 |
4201 |
Synonyms:
2,4-DIAMINO-6-PIPERIDINOPYRIMIDINE 3-OXIDE
6-PIPERIDIN-1-YLPYRIMIDINE-2,4-DIAMINE 3-OXIDE
Alostil
Apo-gain
Loniten
Lonolox
MEN'S ROGAINE
MINODYL
MINOSSIDILE
MINOXIDIL
MINOXIDIL EXTRA STRENGTH
Minoxidilum
Minoximen
|
Normoxidil
Regaine
REGAINE FOR MEN
REGAINE FOR WOMEN
Riup
Rogaine
ROGAINE EXTRA STRENGTH
Rogaine®
THEROXIDIL
Tricoxidil
U-10858
WOMEN'S ROGAINE
|
|
36 |
|
Tolvaptan |
Approved |
Phase 3 |
|
150683-30-0 |
216237 |
Synonyms:
JINARC
JYNARQUE
OPC-41061
OPC-41061(TOLVAPTAN)
|
OPC-41061|Samsca®
SAMSCA
TOLVAPTAN
|
|
37 |
|
Metformin |
Approved |
Phase 3 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
38 |
|
Hydrochlorothiazide |
Approved, Vet_approved |
Phase 3 |
|
58-93-5 |
3639 |
Synonyms:
3,4-Dihydrochlorothiazide
6-CHLORO-1,1-DIOXO-3,4-DIHYDRO-2H-1$L^{6},2,4-BENZOTHIADIAZINE-7-SULFONAMIDE
Acuretic
Aldactazide
Aldoril
APO-HYDRO
Apo-hydro®
Apresazide
Aquarills
Aquarius
Bremil
Caplaril
Capozide
Chlorosulthiadil
Chlorothiazide
Chlorsulfonamidodihydrobenzothiadiazine dioxide
Chlorzide
Cidrex
COTAREG
Dichlorosal
Dichlorotride
Dichlothiazide
Dichlotiazid
Dichlotride
Diclotride
Dicyclotride
Dihydrochlorothiazid
Dihydrochlorothiazide
Dihydrochlorothiazidum
Dihydrochlorurit
Dihydrochlorurite
Dihydroxychlorothiazidum
Direma
Disalunil
Diu-Melusin
Diuril
Drenol
Dyazide
ESI879
Esidrex
Esidrix
ESIDRIX (TN)
Esimil
Fluvin
HCT
HCTZ
HCZ
Hidril
Hidrochlortiazid
Hidroclorotiazida
Hidroronol
Hidrotiazida
Hydril
|
Hydro-aquil
Hydrochloro thiazide
Hydrochlorothiazid
HYDROCHLOROTHIAZIDE
Hydrochlorothiazide intensol
Hydrochlorothiazidum
Hydrochlorthiazide
Hydro-D
Hydrodiuretic
Hydrodiuril
Hydro-diuril
Hydropres
Hydrosaluric
Hydrothide
Hydrozide
Hypothiazid
Hypothiazide
Hyzaar
Idrotiazide
Inderide
Ivaugan
Jen-diril
Lopressor HCT
Lotensin HCT
Maschitt
Maxzide
Megadiuril
Microzide
Moduretic
Nefrix
Neo-codema
Neoflumen
Newtolide
NSC-53477
Oretic
Panurin
Prinzide
Ro-hydrazide
Sectrazide
Ser-ap-es
Servithiazid
SU-5879
Thiaretic
Thiuretic
Thlaretic
Timolide
Unipres
Urodiazin
Vaseretic
Vetidrex
Ziac
Zide
|
|
39 |
|
Sirolimus |
Approved, Investigational |
Phase 2, Phase 3 |
|
53123-88-9 |
5284616 6436030 |
Synonyms:
(-)-Rapamycin
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
Antibiotic ay 22989
AY-22989
AY-22989|Fyarro® (sirolimus albumin-bound particles)|Rapamune®|rapamycin|WY-090217
L04AA10
NSC-226080
Perceiva
RAPA
Rapammune
|
Rapamune
Rapamycin
Rapamysin
RPM
Sirolimus
Sirolimús
Sirolimusum
SM-88 COMPONENT SIROLIMUS
WY-090217
|
|
40 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 2, Phase 3 |
|
22916-47-8 |
4189 |
Synonyms:
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
Brentan
CONOFITE
Dactarin
DERMAZOLE
DUMICOAT
Esteve brand OF miconazole
florid(nitrate)|Monistat®|R-14889
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
LORAMYC
MCZ
MICATIN
|
Miconasil nitrate
Miconazol
Miconazole
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazolum
Monistat
MONISTAT-3
MONISTAT-DERM
Nitrate, miconasil
Nitrate, miconazole
NSC-170986
Oravig
VUSION
|
|
41 |
|
Clotrimazole |
Approved, Vet_approved |
Phase 2, Phase 3 |
|
23593-75-1 |
2812 |
Synonyms:
(Chlorotrityl)imidazole
1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole
1-(a-(2-Chlorophenyl)benzhydryl)imidazole
1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole
1-(O-Chloro-a,a-diphenylbenzyl)imidazole
1-(O-Chloro-alpha,alpha-diphenylbenzyl)imidazole
1-(O-Chlorotrityl)imidazole
1-(O-Chloro-α,α-diphenylbenzyl)imidazole
1-(Α-(2-chlorophenyl)benzhydryl)imidazole
ABTRIM
ACTAVALL
Bay b 5097
BAY-5097
Bayer brand 1 OF clotrimazole
Bayer brand 2 OF clotrimazole
CANDIDEN
Canesten
Canesten 1-day cream combi-pak
Canesten 1-day therapy
Canesten 3-day therapy
Canesten 6-day therapy
CANESTEN AF
Canesten combi-pak 1-day therapy
Canesten combi-pak 3-day therapy
Canesten cream
CANESTEN CRM COMBI
CANESTEN INTERNAL
Canesten solution
CANESTEN VC
Canesten®|Lotrimin®
Canestine
Chlotrimazole
Clotrimaderm
Clotrimaderm cream
Clotrimazol
CLOTRIMAZOLE
Clotrimazole schering brand
Clotrimazolum
Desamix F
Empecid
FB b 5097
Fem care
FemCare
FUNGEDERM
GNF-PF-3499
Gyne lotrimin
Gyne-lotrimin
Gyne-lotrimin 3
Gyne-lotrimin 3 combination pack
Gyne-lotrimin combination pack
Gyne-lotrimin3
Gyne-lotrimin3 combination pack
|
Gynix
Kanesten
Klotrimazole
Lopac-C-6019
Lotrimax
Lotrimin
LOTRIMIN (TN)
Lotrimin af
Lotrimin af cream
Lotrimin af jock-itch cream
Lotrimin af lotion
Lotrimin af solution
Lotrimin cream
Lotrimin lotion
Lotrimin solution
Lotrisone
MASNODERM
mono-Baycuten
Monobaycuten
Mycelax
Mycelex
MYCELEX (TN)
Mycelex 7
Mycelex cream
Mycelex g
Mycelex otc
Mycelex solution
Mycelex troches
Mycelex twin pack
Mycelex: mycosporinrimazole
Mycelex-7
Mycelex-7 combination pack
Mycelex-g
MYCIL GOLD
Myclo cream
Myclo solution
Myclo spray solution
Myclo-gyne
Mycosporin
Mykosporin
Neo-zol cream
NSC-257473
Otomax
Pedisafe
Prestwick_120
PRIVACOM
Rimazole
Schering brand OF clotrimazole
Tibatin
Trimysten
Trivagizole 3
Veltrim
|
|
42 |
|
Everolimus |
Approved |
Phase 2, Phase 3 |
|
159351-69-6 |
70789204 6442177 |
Synonyms:
001, RAD
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-HYDROXYETHYL)RAPAMYCIN
Afinitor
AFINITOR DISPERZ
Afinitor®|Certican®|RAD-001|RAD001|rapamycin, 42-O-(2-hydroxyethyl)-|Zortress®
Certican
EVEROLIMUS
évérolimus
RAD 001
|
RAD 666
RAD, SDZ
RAD001
RAD-001
RAD-666
SDZ RAD
SDZ-RAD
VOTUBIA
ZORTRESS
|
|
43 |
|
Benzocaine |
Approved, Investigational |
Phase 2, Phase 3 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
44 |
|
Tannic acid |
Approved |
Phase 2, Phase 3 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
45 |
|
Triptolide |
Investigational |
Phase 3 |
|
38748-32-2 |
5589 |
Synonyms:
|
46 |
|
Alkylating Agents |
|
Phase 3 |
|
|
|
47 |
|
Antineoplastic Agents, Alkylating |
|
Phase 3 |
|
|
|
48 |
|
Contraceptive Agents, Male |
|
Phase 3 |
|
|
|
49 |
|
Contraceptive Agents |
|
Phase 3 |
|
|
|
50 |
|
Pharmaceutical Solutions |
|
Phase 3 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 162)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease |
Unknown status |
NCT03596957 |
Phase 4 |
Tolvaptan |
2 |
Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients |
Unknown status |
NCT00541853 |
Phase 4 |
Candesartan;Candesartan and Cilnidipine;Candesartan plus non-CCB agents |
3 |
A Multicenter, Randomized, Placebo-controlled, Double-blind Study on the Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease (ESRD) in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
Completed |
NCT00414440 |
Phase 4 |
Placebo;Everolimus |
4 |
Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease |
Completed |
NCT03949894 |
Phase 4 |
Tolvaptan |
5 |
Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD |
Completed |
NCT02494141 |
Phase 4 |
Curcumin |
6 |
Treatment of Vascular Stiffness in Patients With Autosomal Dominant Polycystic Kidney Disease |
Recruiting |
NCT05228574 |
Phase 4 |
Amiloride Hcl 5mg Tab |
7 |
Statin Therapy in Patients With Early Stage ADPKD |
Recruiting |
NCT03273413 |
Phase 4 |
Pravastatin;Placebo |
8 |
Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease - The Vienna RAP Study |
Unknown status |
NCT02055079 |
Phase 3 |
Sirolimus;Placebo |
9 |
Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease. A Phase 3a, Indipendent, Multicentre, Two Parallel Arms, Randomized Controlled Trial |
Unknown status |
NCT03764605 |
Phase 3 |
Metformin;Tolvaptan |
10 |
Randomized Controlled Trial of Triptolide-Containing Formulation for Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
Unknown status |
NCT02115659 |
Phase 3 |
Triptolide-Containing Formulation;Placebo |
11 |
The DIPAK 1 Study: A Randomised, Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in ADPKD |
Unknown status |
NCT01616927 |
Phase 3 |
Lanreotide |
12 |
An Open-label, Prospective Clinical Trial to Evaluate the Effectiveness and Safety of Sirolimus to Reduce Cyst Growth in ADPKD Patients With Massive Polycystic Liver |
Unknown status |
NCT01680250 |
Phase 2, Phase 3 |
Sirolimus |
13 |
Open-Label Extension of the LOCKCYST Trial, LOCKCYST: Long Acting Lnareotide as as Volume Reducing Treatment of Polycystic Livers |
Unknown status |
NCT00771888 |
Phase 2, Phase 3 |
lanreotide |
14 |
A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablets Regimens in Adult Subjects With Autosomal Dominant Polycystic Kidney Disease |
Completed |
NCT00428948 |
Phase 3 |
Tolvaptan;Placebo |
15 |
EFFECT OF SOMATOSTTIN ON EARLY DIASTOLIC LEFT VENTRICULAR FUNCTION IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A MATCHED-COHORT, SPECKLE-TRACKING ECHOCARDIOGRAPHIC STUDY |
Completed |
NCT02119013 |
Phase 2, Phase 3 |
Octeotride;Placebo |
16 |
A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Immediate-release Tolvaptan (OPC-41061, 30 mg to 120 mg/Day, Split Dose) in Subjects With Autosomal Dominant Polycystic Kidney Disease |
Completed |
NCT02251275 |
Phase 3 |
Tolvaptan |
17 |
A Phase 3b, Two-part, Multicenter, One Year Randomized, Double-blind, Placebo-controlled Trial of the Safety, Pharmacokinetics, Tolerability, and Efficacy of Tolvaptan Followed by a Two Year Open-label Extension in Children and Adolescent Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
Completed |
NCT02964273 |
Phase 3 |
Phase A Tolvaptan;Placebo Phase A;Phase B Tolvaptan |
18 |
Effect of Long-acting Somatostatin on Liver in Autosomal Dominant Polycystic Kidney Disease |
Completed |
NCT02119052 |
Phase 2, Phase 3 |
octeotride;placebo |
19 |
An Open-labelled Multicenter Randomized Study on the Efficacy of Everolimus in Reducing Total Native Kidney Volume in Kidney Transplanted Patients With Autosomal Dominant Polycystic Kidney Disease |
Completed |
NCT02134899 |
Phase 3 |
Everolimus;Calcineurin inhibitors maintenance |
20 |
Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease |
Completed |
NCT00456365 |
Phase 3 |
pravastatin;Placebo |
21 |
Sirolimus (Rapamune®) for Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD): a Randomized Controlled Study. |
Completed |
NCT00346918 |
Phase 3 |
Sirolimus |
22 |
Effect of a Long-acting Somatostatin on Disease Progression in Nephropathy Due to Autosomal Dominant Polycystic Kidney Disease: a Long-term Three Year Follow up Study |
Completed |
NCT00309283 |
Phase 3 |
Long-acting somatostatin |
23 |
A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002] |
Completed |
NCT01022424 |
Phase 3 |
OPC-41061 |
24 |
Multi-center, Open-label, Extension Study to Evaluate the Long-term Efficacy and Safety of Oral Tolvaptan Tablet Regimens in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
Completed |
NCT01214421 |
Phase 3 |
Tolvaptan |
25 |
A Phase 3b, Multi-center, Randomized-withdrawal, Placebo-controlled, Double-blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/Day, Split-dose) in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease |
Completed |
NCT02160145 |
Phase 3 |
Tolvaptan (OPC-41061);Placebo |
26 |
A Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan] |
Completed |
NCT01280721 |
Phase 3 |
tolvaptan |
27 |
A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL TO ASSESS THE EFFECTS OF LONG-ACTING SOMATOSTATIN (OCTREOTIDE LAR) THERAPY ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND MODERATE TO SEVERE RENAL INSUFFICIENCY |
Completed |
NCT01377246 |
Phase 3 |
Octreotide-LAR |
28 |
Lanreotide In Polycystic Kidney Disease Study |
Completed |
NCT02127437 |
Phase 3 |
Lanreotide;saline |
29 |
Low Osmolar Diet and Adjusted Water Intake for Vasopressin Suppression in ADPKD |
Completed |
NCT02225860 |
Phase 2, Phase 3 |
|
30 |
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney |
Completed |
NCT01853553 |
Phase 3 |
Spironolactone;Sugar pill |
31 |
Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD |
Completed |
NCT03803124 |
Phase 3 |
Tolvaptan;Placebo |
32 |
Pilot Study Of Long-Acting Octreotide (Octreotide LAR® Depot) In The Treatment Of Patients With Severe Polycystic Liver Disease |
Completed |
NCT00426153 |
Phase 2, Phase 3 |
Octreotide;Placebo |
33 |
Long-Acting Lanreotide as a Volume Reducing Treatment of Polycystic Livers |
Completed |
NCT00565097 |
Phase 2, Phase 3 |
Placebo;Lanreotide |
34 |
HALT Progression of Polycystic Kidney Disease Study B |
Completed |
NCT01885559 |
Phase 3 |
Lisinopril;Telmisartan;Placebo |
35 |
HALT Progression of Polycystic Kidney Disease Study A |
Completed |
NCT00283686 |
Phase 3 |
Lisinopril;Telmisartan;Placebo |
36 |
A Phase 3 Trial of Bardoxolone Methyl in Patients With Autosomal Dominant Polycystic Kidney Disease |
Recruiting |
NCT03918447 |
Phase 3 |
Bardoxolone methyl oral capsule;Placebo oral capsule |
37 |
An Extended Access Program to Assess Long Term Safety of Bardoxolone Methyl in Patients With Chronic Kidney Disease |
Recruiting |
NCT03749447 |
Phase 3 |
Bardoxolone methyl |
38 |
A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 Days to Less Than 18 Years of Age With Autosomal Recessive Polycystic Kidney Disease (ARPKD) |
Recruiting |
NCT04782258 |
Phase 3 |
Tolvaptan Suspension;Tolvaptan Tablets |
39 |
A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 Days to Less Than 12 Weeks of Age With Autosomal Recessive Polycystic Kidney Disease (ARPKD) |
Recruiting |
NCT04786574 |
Phase 3 |
Tolvaptan (OPC-41061) |
40 |
Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD): A Randomised Placebo-Controlled Trial |
Not yet recruiting |
NCT04939935 |
Phase 3 |
Metformin XR |
41 |
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life |
Not yet recruiting |
NCT05373264 |
Phase 3 |
Hydrochlorothiazide 25 mg;Placebo |
42 |
Multicenter, Open-label, Extension Study to Characterize the Long-term Efficacy and Safety of Early Versus Delayed Treatment With Venglustat (GZ/SAR402671) in Patients at Risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
Terminated |
NCT04705051 |
Phase 3 |
Venglustat GZ402671 |
43 |
An Open-Label Study of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Previously Experienced Abnormal Liver Chemistry Test Results While Receiving Tolvaptan: The ALERT Study |
Terminated |
NCT04152837 |
Phase 3 |
Lixivaptan |
44 |
A Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants With Autosomal Dominant Polycystic Kidney Disease Consisting of a 1-year Double-blind, Placebo-controlled, Randomized Phase and a 1-year Open-label Phase: The ACTION Study |
Terminated |
NCT04064346 |
Phase 3 |
Lixivaptan;Placebo |
45 |
Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at Risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
Terminated |
NCT03523728 |
Phase 2, Phase 3 |
Venglustat;Placebo |
46 |
PA-ADPKD-304: A Phase 3, Open-label, Roll-over Study to Assess Long-term Safety of Lixivaptan in Participants With Autosomal Dominant Polycystic Kidney Disease Who Completed Study PA-ADPKD-303: The ALERT Study |
Terminated |
NCT05208866 |
Phase 3 |
Lixivaptan |
47 |
EFFECTS OF SIROLIMUS ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND SEVERE RENAL INSUFFICIENCY |
Terminated |
NCT01223755 |
Phase 2, Phase 3 |
Sirolimus;conventional therapy |
48 |
Rapamycin as Treatment for ADPKD: The Role of Biomarkers in Predicting a Response to Therapy |
Terminated |
NCT00920309 |
Phase 2, Phase 3 |
Rapamycin |
49 |
Everolimus on CKD (Chronic Kidney Disease) Progression in ADPKD Patients |
Terminated |
NCT01009957 |
Phase 2, Phase 3 |
Everolimus |
50 |
A Randomized, Open-label Study Investigating the Effect of Bilateral Renal Artery Sympathetic Denervation by Catheter-based Radiofrequency Ablation on Blood Pressure and Disease Progression in Autosomal Dominant Polycystic Kidney Disease |
Unknown status |
NCT01932450 |
Phase 2 |
antihypertensive drugs |
|